Table 1 Patient characteristics (N=50)

From: ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF

  ESHAP (N=26) HDCY (N=24) P-value
  No. % No. %  
Participating centers      1.0
 AMC 24 92 22 92  
 YUMC 2 8 2 8  
Age (years)
 Median (range) 45 (17–64)   45 (16–63)   0.915
Male sex 19 73 19 79 0.745
WHO type      0.872
 DLBL 14 54 12 50  
 NK/TL 2 8 1 4  
 PTCL 5 19 5 21  
 LBL 3 12 5 21  
 Others 2 8 1 4  
Bone marrow involvement 10 39 3 13 0.057
Disease status      0.042
 CR/PR to first-line therapy 9 35 16 70  
 CR/PR to second-line therapy 16 62 6 26  
 Refractory to second-line therapy 1 4 1 4  
 Prior radiotherapy 6 23 4 17 0.728
No. of chemotherapy regimens      0.001
 1 7 27 14 58  
 2 3 12 8 33  
 3 12 46 2 8  
 4 4 15 0 0  
Prior chemotherapy regimen      0.01
 Cy containing 9 35 18 75  
 DDP containing 4 17 0 0  
 Both Cy and DDP containing 13 48 6 25  
No. of prior chemotherapy cycles      0.151
 Median (range) 6 (3–13)   5 (3–10)   
 Mean±s.d. 7.2±3.1   5.9±2.4   
  1. HDCY=high-dose cyclophosphamide; AMC=Asan Medical Center; YUMC=Yeungnam University Medical Center; DLBL=diffuse large B-cell lymphoma; NK/TL=extranodal NK/T-cell lymphoma; PTCL=peripheral T-cell lymphoma; LBL=lymphoblastic lymphoma; DDP=cisplatin.